Online inquiry

IVTScrip™ mRNA-Anti-CD40, CHIR-12,12(Cap 0, 5-Methyl-CTP & Pseudo-UTP, 30 nt-poly(A))   (CAT#: GTTS-WQ5845MR)

This product GTTS-WQ5845MR is a type of mRNA having 30 nt poly(A) tail and modified with Cap 0 & 5-Methyl-CTP & Pseudo-UTP. It ecodes the monoclonal antibody that targets CD40 gene. The antibody can be applied in Chronic lymphocytic leukemia (CLL), Multiple myeloma (MM) research.
Specifications
Product type mRNA
Modified bases 5-Methyl-CTP & Pseudo-UTP
5' Cap Cap 0
Species Homo sapiens
RefSeq NM_001250.6
Applications Gene therapy research
Format Powder
Quantity 100 µg
Purification oligo-dT affinity purification
Target Gene
Gene ID 958
UniProt ID P25942
Download
Download resources about mRNA therapeutics development to boost your research.
CUSTOMER REVIEWS and Q&As

There are currently no Customer reviews or questions for IVTScrip™ mRNA-Anti-CD40, CHIR-12,12(Cap 0, 5-Methyl-CTP & Pseudo-UTP, 30 nt-poly(A)) (GTTS-WQ5845MR). Click the button above to contact us or submit your feedback about this product.
See other products
CAT Product Name Product Type CDs
GTTS-WQ14115MR IVTScrip™ mRNA-Anti-NGF, aNGF75(Cap 0, N1-Methylpseudo-UTP, 120 nt-poly(A)) mRNA aNGF75
GTTS-WQ673MR IVTScrip™ mRNA-Anti-CD276, 8H9(Cap 0, 2-Thio-UTP, 30 nt-poly(A)) mRNA 8H9
GTTS-WQ7337MR IVTScrip™ mRNA-Anti-VTCN1, FPA-150(Cap 1, Pseudo-UTP, 30 nt-poly(A)) mRNA FPA-150
GTTS-WQ11574MR IVTScrip™ mRNA-Anti-CD276, MG-A271(Cap 1, 2-Thio-UTP, 30 nt-poly(A)) mRNA MG-A271
GTTS-WQ7471MR IVTScrip™ mRNA-Anti-TNFRSF4, GBR-830(Cap 0, 5-Methyl-CTP, 120 nt-poly(A)) mRNA GBR-830
GTTS-WQ6900MR IVTScrip™ mRNA-Anti-Alkaline phosphatase substitute, ENB-0040(Cap 0, N1-Methylpseudo-UTP, 30 nt-poly(A)) mRNA ENB-0040
GTTS-WQ10663MR IVTScrip™ mRNA-Anti-S, LY-3819253(Cap 0, 5-Methyl-CTP, 120 nt-poly(A)) mRNA LY-3819253
GTTS-WQ13247MR IVTScrip™ mRNA-Anti-PCSK9, PF-05335810(Cap 0, 2-Thio-UTP, 120 nt-poly(A)) mRNA PF-05335810
All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.
webinar

EABR Nanoparticles as a Platform Technology for Hybrid mRNA Vaccine Development

November 20th, 2024, 2 PM–3 PM EST

REGISTER NOW